Action PHIO PHIO PHARMACEUTICALS CORP.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Phio Pharmaceuticals Corp.

Actions

PHIO

US71880W4024

Marché Fermé - Nasdaq
Autres places de cotation
 22:30:00 03/05/2024 		Varia. 5j. Varia. 1 janv.
0,8197 USD +5,67% Graphique intraday de Phio Pharmaceuticals Corp. +20,19% +7,86%
22/04 Phio Pharmaceuticals Corp. présente de nouvelles données sur son principal produit clinique candidat, le PH-762 CI
16/04 Phio Pharmaceuticals annonce ses prochaines présentations lors de la 81e réunion annuelle de la Society for Investigative Dermatology (SID) CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
National Spotlight Features Phio’s Innovative RNAi Technology Platform
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
North American Morning Briefing : Stocks Seen -2-
Phio Pharmaceuticals Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
Phio Pharmaceuticals Corp. Presents Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
Phio Pharmaceuticals Corp. Announces Addition of Clinical Trial Sites At Banner Md Anderson Cancer Center, the George Washington University, and Integrity Research
Phio Pharmaceuticals Secures Patent for Compounds Treating Age Related Skin Disorders
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders
Phio Pharmaceuticals Corp. Announces Patent Granted by Uspto, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action PHIO
  4. Actualités Phio Pharmaceuticals Corp.
  5. Autres langues